文献速递中毒与环境急症重症综合管理与镇静镇痛

利用血浆浓度优化急性敌草快中毒的体外治疗:一项多中心回顾性队列研究

Leveraging plasma concentrations to optimize extracorporeal treatment in acute diquat poisoning: a multi-center retrospective cohort study.
PubMed 文献 · Clin Toxicol (Phila) · 2025-12-08
一句话结论急性敌草快中毒患者就诊时血浆敌草快浓度可指导个体化体外治疗:低浓度组(<100 μg/L)全部存活,高浓度组(≥1,000 μg/L)血液灌流联合连续性静脉-静脉血液透析滤过较单用血液灌流可能改善生存。

这项多中心回顾性队列研究纳入2022年2月至2023年7月间163例急性敌草快中毒患者,按急诊就诊时血浆敌草快浓度分为低(<100 μg/L)、中(100-1,000 μg/L)、高(≥1,000 μg/L)三组,评估单用血液灌流与血液灌流联合连续性静脉-静脉血液透析滤过两种体外治疗方案。低浓度组66例全部存活,与所用体外治疗无关;中、高浓度组中5例拒绝体外治疗者死亡,接受体外治疗的92例病死率为48.9%。高浓度组中,血液灌流联合连续性静脉-静脉血液透析滤过者病死率76.7%且生存概率优于单用血液灌流者(后者无存活者)。在联合治疗者中,幸存者从血液灌流结束到启动连续性静脉-静脉血液透析滤过的平均时间间隔短于死亡者(3.7 h vs 4.7 h)。作者认为获取血浆敌草快浓度对指导体外治疗方案、改善预后可能有重要价值,未来需随机试验评估体外治疗的最佳应用。

要点

  • 低浓度组(<100 μg/L)66例全部存活,无论采用何种体外治疗,提示该组可能无需积极体外清除。
  • 中、高浓度组中5例拒绝体外治疗者全部死亡;接受体外治疗的92例病死率48.9%。
  • 高浓度组(≥1,000 μg/L)血液灌流联合连续性静脉-静脉血液透析滤过者病死率76.7%,单用血液灌流者无存活者。
  • 联合治疗者中,幸存者从血液灌流结束到启动连续性静脉-静脉血液透析滤过的平均间隔短于死亡者(3.7 h vs 4.7 h)。
  • 作者认为就诊时血浆敌草快浓度可能有助于指导个体化体外治疗方案,未来需随机试验评估体外治疗的最佳应用。

适用人群与场景

  • 2022年2月至2023年7月收治的急性敌草快中毒患者,共163例,多中心回顾性队列。
  • 按急诊就诊时血浆敌草快浓度分为低(<100 μg/L)、中(100-1,000 μg/L)、高(≥1,000 μg/L)三组。

诊断标准与关键阈值

  • 按急诊就诊时血浆敌草快浓度分组:低<100 μg/L,中100-1,000 μg/L,高≥1,000 μg/L。

处置流程与药物剂量

  • 评估的体外治疗方案包括单用血液灌流,以及血液灌流联合连续性静脉-静脉血液透析滤过。
  • 高浓度组(≥1,000 μg/L)接受血液灌流联合连续性静脉-静脉血液透析滤过者病死率76.7%,单用血液灌流者无存活者。
  • 联合治疗者中,幸存者从血液灌流结束到启动连续性静脉-静脉血液透析滤过的平均间隔为3.7 h,死亡者为4.7 h。
  • 中、高浓度组中5例拒绝体外治疗者死亡。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入163例急性敌草快中毒患者。
  • 低浓度组66例全部存活,与所用体外治疗无关。
  • 中、高浓度组中5例拒绝体外治疗者死亡;接受体外治疗的92例病死率为48.9%。
  • 高浓度组中,血液灌流联合连续性静脉-静脉血液透析滤过者病死率76.7%且生存概率优于单用血液灌流者(后者无存活者)。
  • 联合治疗者中,幸存者从血液灌流结束到启动连续性静脉-静脉血液透析滤过的平均间隔短于死亡者(3.7 h vs 4.7 h)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为获取血浆敌草快浓度对指导体外治疗方案、改善急性敌草快中毒患者预后可能有重要价值。
  • 作者认为未来需随机试验评估体外治疗的最佳应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Diquat poisoning is common in Asia and the optimal enhanced elimination strategy is unknown. This study aimed to evaluate the clinical value of plasma diquat concentrations in guiding personalized extracorporeal treatment regimens for patients with acute diquat poisoning.

METHODS: This multi-center retrospective cohort study included 163 patients with acute diquat poisoning admitted between February 2022 and July 2023. Patients were divided into three groups based on plasma diquat concentrations measured upon presentation to the emergency department: low (<100 μg/L), medium (100-1,000 μg/L), and high (≥1,000 μg/L). The evaluated extracorporeal treatment regimens included hemoperfusion alone and a combination of hemoperfusion with continuous veno-venous hemodiafiltration. Kaplan-Meier survival curves were used to estimate cumulative survival probabilities, with survival probabilities compared using log-rank tests.

RESULTS: All 66 patients survived in the low concentration group, regardless of the extracorporeal treatment used. In the medium and high concentration groups, five patients who refused extracorporeal treatment died, whereas 92 patients who received extracorporeal treatment had a case fatality rate of 48.9%. In the high concentration group, patients receiving hemoperfusion combined with continuous veno-venous hemodiafiltration had a case fatality rate of 76.7% and better survival probabilities, compared to hemoperfusion-only patients, which had no survivors. Additionally, among those treated with a combination of hemoperfusion and continuous veno-venous hemodiafiltration, the time interval from the end of hemoperfusion session to the initiation of continuous veno-venous hemodiafiltration was, on average, shorter for survivors than deaths (3.7 h versus 4.7 h).

DISCUSSION: This retrospective observational study of diquat poisoned patients highlights the potential for personalized extracorporeal treatment regimens using an initial plasma diquat concentration. Future randomized trials are warranted to evaluate the optimal use of extracorporeal treatments.

CONCLUSION: Obtaining plasma diquat concentrations may be of great value for guiding extracorporeal treatment regimens to improve prognosis in patients with acute diquat poisoning.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Ling Y, Mao Z, Zhou C, et al. Leveraging plasma concentrations to optimize extracorporeal treatment in acute diquat poisoning: a multi-center retrospective cohort study. Clin Toxicol (Phila). 2025. PMID: 41355765. doi:10.1080/15563650.2025.2591798

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。